Our Mission

To accelerate the availability and uptake of life-saving technologies and medications for patients who need them most.

Learn more about us.

The Problems We Help Solve

Global health challenges are vast! Thousands of people die every day from preventable or treatable diseases. The reasons are myriad. We focus on three:

Medication Non-adherence

Most medications are not taken as prescribed, even for life-threatening conditions. Reasons range from simple forgetfulness to more complex side-effect or behavioral issues. When this happens, patients reduce their chances of getting well, increase disease transmission, and build resistance.

See how we help.
Medication Non-adherence

Lack of Access to Medications

Life-saving medications are not available or simply not affordable to patients or even health systems in high disease-burden parts of the World. Lack of affordable access to medications results in increased disease transmission and increased mortality — even for treatable or curable conditions.

We're building access.
Lack of Access to Medications

Innovation Delivery Gaps

We believe that the problem is NOT the absence of innovative treatments or a dearth of proven-effective innovations to address global health challenges. The problem is that we struggle to bring these innovations at scale, conveniently, and affordably to those who need them most around the world.

How we ignite growth.
Innovation Delivery Gaps

Our Story

Where it all began.

Sometimes big ideas take years to come to fruition. Other times a single chance meeting sparks an idea that changes everything. While we may not have realized it at the time, the founding of The Arcady Group was both. Our experience transforming the Walmart pharmaceutical supply chain combined with the realization that our process was transferable and repeatable in global health, set the foundation for our impact today.

Read our story.

Recent News & Insights

Sharing our learnings to accelerate your journey.

Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomized superiority trial

 Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomized superiority trial 150 150 The Arcady Group

Arcady Group team members co-authored a paper that is now available with open access online in The Lancet. The article entitled Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomized superiority trial aimed to evaluate the effect of a daily reminder medication monitor, monthly review of adherence data by the health-care provider, and differentiated care for patients with adherence issues, on tuberculosis treatment adherence and outcomes.  

Global Health Work Continues with New Grant Awards

 Global Health Work Continues with New Grant Awards 150 150 The Arcady Group

We are pleased to announce that The Arcady Group has been awarded two new contracts from the Bill & Melinda Gates Foundation and that a third contract with the foundation has been extended and supplemented.

National Academies’ Forum on Microbial Threats

 National Academies’ Forum on Microbial Threats 610 557 The Arcady Group

…

Workshop: A Step-by-Step Guide to Deploying DATs for TB

 Workshop: A Step-by-Step Guide to Deploying DATs for TB 0 0 The Arcady Group

…

Making Cough Count: A TB Cough Consultation

 Making Cough Count: A TB Cough Consultation 582 297 The Arcady Group

…

India TB Summit

 India TB Summit 2251 1614 The Arcady Group

…

View Our Resources
Join Us On LinkedIn
Contact Us
Accelerating the availability and uptake
of life-saving technologies and medications for patients who need them most.
Meet our leadership.

Navigation

Home
Who We Are
Our Work
New & Resources
Contact Us

Latest Resources

Tuberculosis
Toolkits
Adherence
Innovative Technologies
Special Reports

Stay Connected

©2022 The Arcady Group. All Rights Reserved.

Start Typing
Back to top